Kornimate/medical-research-clean huggingface dataset:
relieving surgical pain and nausea with light therapy

Conditions: Pain, Postoperative; Nausea and Vomiting, Postoperative

Summary: the goal of this clinical trial is to investigate the effectiveness of colored (green and blue lens) glasses as a non-pharmacological method in relieving post-surgical pain and postoperative nausea in kidney donors. the main hypothesis it aims to test: h1: postoperative use of green-lensed glasses by patients who are kidney donors is effective in relieving surgical pain and postoperative nausea. h2: postoperative use of blue-lensed glasses by patients who are kidney donors is effective in relieving surgical pain and postoperative nausea. researchers will compare the blue-lens glasses and green-lens glasses groups to the transparent (colorless) glasses group and the non-glasses group to see if the colored lenses have an effect on postoperative pain and nausea. participants in the intervention groups will be asked * to wear the glasses (according to their randomly assigned group (blue/green/colorless/), immediately after they admitted to the ward postoperatively, at least 8 hours in a day, until their discharge * to respond the pain and nausea assessment (every 2 hours during postop day 1 and every 4 hours during postop day 2) until their discharge participants in the control group will be asked - to respond the pain and nausea assessment (every 2 hours during postop day 1 and every 4 hours during postop day 2) until their discharge

since the hospital's architecture and clinical operation where the data will be collected have features that prevent patients from different groups from meeting, the single blind feature can be preserved. the pain assessment of the patients will be made with the numerical pain scale, and the nausea assessment will be made with the numerical nausea rating scale. in addition, data will be collected with the patient information form prepared by the researchers in line with the literature.

Eligibility criteria:
inclusion criteria: * being a donor for kidney transplantation * not having an obstacle to wearing glasses * being able to communicate verbally exclusion criteria: * being color blind • developing post-operative complications during the study period

Keywords: colored-lens glasses postoperative pain organ donor kidney transplantation postoperative nausea blue light green light
renal replacement therapy plus extracorporeal carbon dioxide removal

Conditions: Acute Kidney Injury

Summary: this study aims to assess whether in patients with acute kidney injury (aki) requiring mechanical ventilation, a strategy that combines renal replacement therapy (rrt) and extracorporeal carbon dioxide removal (ecco2r) allows reduction of tidal volume and plateau pressure. systemic inflammatory response and safety variables will also be analysed.


Eligibility criteria:
inclusion criteria: * patients with acute kidney injury (aki) requiring renal-replacement therapy and mechanical ventilation of duration ≥ 48 hours exclusion criteria: * little chance of survival at 24 h (according to clinical judgment), pregnancy, mechanical ventilation with expected duration lower than 48h, age under 18 and over 90

Keywords: aki extracorporeal carbon dioxide removal renal replacement therapy mechanical ventilation
evaluation of the impact of touch relaxation in sedated intubated patients hospitalized in intensive care at niort hospital

Conditions: Reaction Anxiety; Difficult or Failed Intubation

Summary: this is a randomized prospective study. this objective is the impact of "relaxing touch" on the use of chemical restraint for patients in intensive care from the lifting of sedation until extubation.


Eligibility criteria:
inclusion criteria: * male or female over 18 years of age * intubated and sedated man or woman * extubation within 48 hours * intubation of more than 48 hours in total * patient in intensive care at niort hospital * the trusted person or referent accepting the patient's participation * patient affiliated to the social security system exclusion criteria: * known pregnancy * patient who refused to participate in the study after the fact * patients under long-term antidepressant treatment (treatment longer than 3 months) * patients under guardianship or curatorship * patient deprived of liberty * skin lesions on the hands/feet/head (wounds, erythema, burns, bedsores, phlyctenes) * inclusion in another clinical study

Keywords: chemical restraint intensive care intubation
dermogenesis with mesenchymal stem cells

Conditions: Dermal Regeneration

Summary: dermogenesis with mesenchymal stem cells in treating post acne depressed spots

management at two different stages of the course of the disease. first one at the stage of active disease which needs cleansers, antibiotics, retinoids, anti inflammatory agents and hormonal manipulation. once active disease is over, patients report to clinician with depressed spots which are caused by localized dermal disruption and fat atrophy post inflammation or spontaneous epithelial rupture or scratching by the patient. these acne spots are hard to treat due to many reasons. firstly, excision is difficult as size of most of them is small and they are in a large in number. secondly, filling with and without subcision is not adequately addressing the deformity. currently, a combination of filling with synthetic filler or fat and resurfacing by peeling, laser or dermabrasion is in practice. in-spite of all, a treatment is still required to address post acne spots (ice spec spots) adequately.

Eligibility criteria:
inclusion criteria: * acne spots exclusion criteria: * active acne
meropenem dosage strategy based on ppk model

Conditions: Lower Respiratory Tract Infection

Summary: to evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(ppk)-pharmacodynamic(pd) model in lower respiratory tract infection patients.

* subjects:lower respiratory tract infection patients * study design:randomized control study.the patients in study group will accept meropenem therapy with the regimen decided by a software developed from a ppk-pd model. the patients in control group will accept meropenem therapy with the regimen decided by attending physician. * primary endpoint: clinical successful rate of meropenem therapy. the clinical efficiency of meropenem therapy will be evaluated one week later from stop of meropenem therapy. * second endpoint: amount of used antibiotics and bacteriological successful rate.

Eligibility criteria:
inclusion criteria: * sixty years and older patients hospitalized at the peking university third hospital with community-acquired or hospital-acquired lower respiratory tract infection. * bacilli was idolated from lower respiratory tract specimens within 48 hours prior to study enrollment. * the pathogen was sensitive to meropenem. * received broad-spectrum antibiotic therapy less than 24 hours, or no improvement after antibiotic therapy and pathogen was resistant to the used antibiotics. exclusion criteria: * had documented hypersensitivity to carbapenems. * more than one pathogenic gram-negative bacillus was isolated lower respiratory tract specimens. * positive hiv antibody titre. * had known or suspected tuberculosis or other infections caused by gram-positive cocci, viruses or fungi at baseline.

Keywords: infection; meropenem; pharmacokinetics; pharmacodynamics
a study of recormon (epoetin beta) in anemic patients with non-myeloid malignancy

Conditions: Anemia

Summary: this study will examine the efficacy, safety, and effect on hemoglobin levels, of once weekly epoetin beta subcutaneous injections (30,000 international units \[iu\]) in anemic patients with solid tumors. the anticipated study duration is 4 months, and the target sample size is 40 individuals.


Eligibility criteria:
inclusion criteria: * adult patients with a non-myeloid malignancy * anemia exclusion criteria: * transfusion of red blood cells within 2 months of study drug * treatment-resistant hypertension * acute or chronic bleeding (requiring therapy) within 3 months of study drug
pilot study for evaluating the role of f-18 flt pet/ct in therapeutic decision making in non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the objective of this pilot study is to determine whether 18f-flt pet/ct can predict which patients will have poorer progression free survival and overall survival in advanced non-small cell lung cancer (nsclc) after first-line therapy and, therefore, need more aggressive treatment.

standard therapy for patients with advanced nsclc is platinum based doublet chemotherapy. current first-line chemotherapy is usually limited to 4-6 cycles, as prolonging treatment does not result in additional benefit and may often cause further toxicity. until recently, treatment guidelines recommended withholding administration of later-line systemic anti-cancer treatment until disease progression. there are several reports suggesting that maintenance therapy following first-line chemotherapy offers improved survival in advance stage patients. this approach involves the administration of an active treatment immediately after first-line chemotherapy, thus maintaining the clinical benefit initially obtained. however, drug related toxicity and costs are of great concern. there may also be patients with less aggressive disease where an immediate transition to maintenance therapy after first-line results in overtreatment. therefore, selecting patients who require more aggressive treatment or earlier intervention is necessary. if flt pet/ct can discriminate the patients with shorter progression free survival and overall survival in this pilot study, patients could be selected for more aggressive or earlier treatment such as maintenance therapy, and the investigators could expect to prolong survival while reducing the adverse events and costs that will accompany inconsequential therapy with flt pet/ct.

Eligibility criteria:
inclusion criteria: * advanced non-small cell lung cancer (stage iiib, iv) * at least one measurable lesion * performance status (ecog) 0-2 * 1st-line platinum chemotherapy and no progression exclusion criteria: * mixed small cell and non-small cell * uncontrolled brain metastasis * previous malignancy within 5 years (except basal cell carcinoma of skin, carcinoma in situ of uterine cervix) * pregnant or breast feeding * pemetrexed chemotherapy

Keywords: lung cancer f-18 flt pet/ct
impact of vaccination on th2 immunity in infancy

Conditions: Food Hypersensitivity

Summary: the purpose of this study is to assess the responses in the immune system of infants after they receive the vaccine against diphtheria, tetanus, and pertussis (dtap). the investigators will do this by studying the immune cells and allergy responses in the blood prior to and after receipt of the third dtap vaccine.

this is a single-site study of infants who are scheduled to receive their third series (\~6 month) vaccinations, as routine care, to investigate whether the diphtheria, tetanus, and pertussis (dtap) vaccination has an effect on specific immunoglobulin e (ige) levels to milk, egg, or peanut. infants will be assigned to one of two groups depending on the infant's sensitization to milk, egg, and peanut.

Eligibility criteria:
inclusion criteria: * written informed consent from parent/guardian * general good health without other known need for blood draws that would conflict with the study volume requirements * aged 5 months - 7 months, any race/ethnicity, any gender * subjects must not have yet received their third dtap vaccination, which typically is given at 6 months of age. subjects must have previously received two doses of the dtap vaccination, at ages 2 months and 4 months * willingness to return for follow-up testing as defined in the protocol and consent if screening tests indicate eligibility * group 1 participants must have all of the following: * a negative skin prick test to egg, milk, and peanut * a negative ige to egg, milk, and peanut * group 2 participants must have all of the following: * a positive family history of allergic disease * atopic dermatitis not requiring prescription medication * a positive ige to milk, egg, and/or peanut if group 1 enrollment is completed first, participants must have all of the following to be enrolled in group 2: * a family history of atopy * atopic dermatitis not requiring prescription medication if group 2 enrollment is completed first, participants must have all of the following to be enrolled in group 1: -no personal or family history of atopic disease exclusion criteria: * history of anemia requiring any treatment * previous allergic reaction to any food, defined as itching, rash, hives, swelling, vomiting, diarrhea, sneezing, rhinorrhea, wheezing, breathing difficulty, or passing out immediately after food ingestion. * evidence of non-ige-mediated reaction to milk or soy (i.e. milk/soy protein intolerance) or evidence of food protein induced enterocolitis syndrome (fpies) * severe atopic dermatitis (liberally defined as requiring prescription medication) * unable to obtain serum sample for determination of egg, milk and peanut ige levels * use of short-acting anti-histamines (diphenhydramine, etc.) more than one time within 3 days of skin testing or on the day of skin testing * any history of intravenous or oral steroid medication * known underlying immune defect/deficiency or bleeding disorder

Keywords: milk allergy egg allergy peanut allergy infant vaccination
side effects after direct-acting antiviral treatment

Conditions: Chronic Hepatitis c

Summary: the objective of this study was to assess the incidence of side effects after direct-acting antiviral therapy in patients with chronic hepatitis c virus infection.

direct-acting antiviral (daa)-based treatments are today very effective the objective of this study was to assess the incidence of side effects after daa therapy in patients with chronic hepatitis c virus infection.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * hepatitis c virus infection * treatment by direct-acting antiviral combination exclusion criteria: * hiv coinfection
indocyanine green to visualize critical view of safety during laparoscopic cholecystectomy for acute cholecystitis

Conditions: Acute Cholecystitis; Acute; Cholecystitis, Choledocholithiasis; Acute Cholecystitis With Obstruction

Summary: the purpose of this prospective randomized trial is to study the role of indocyanine green (icg) to visualize the critical view of safety during emergency laparoscopic cholecystectomy for patients with acute cholecystitis.

after informing about the study and obtaining consent to participate, patients who are diagnosed with acute cholecystitis and posted for emergency laparoscopic cholecystectomy will be randomly assigned to receive either icg or not as a method to identify the critical view of safety during the operation. the primary outcome is whether there was a precise and satisfactory visualization of the junction between the cystic duct, the common hepatic duct, and the common bile duct by indocyanine green compared to the control group. the time taken to achieve this will be measured in minutes from video recordings of the laparoscopic surgery. the process will be further assessed by a surgeons' satisfaction score. the expected duration of the study will be 12 months involving a total of 80 patients randomized into two groups- 40 patients in the intervention group and 40 patients in the control group. the expected outcome of the study is that icg is more effective than the control group in providing precise and satisfactory visualization of critical view of safety and takes less time. we predict the surgeons to be equally or more satisfied with icg compared to control.

Eligibility criteria:
inclusion criteria: * patient scheduled for emergency laparoscopic cholecystectomy for acute cholecystitis * patient age ≥ 18 years. * patients who consent to take part in the study exclusion criteria: * preoperative planned for open cholecystectomy * allergy towards iodine, iohexol or icg * pregnancy or lactation * renal insufficiency * legally incompetent for any reason * withdrawal of inclusion consent at any time * prisoners

Keywords: acute cholecystitis laparoscopic cholecystectomy critical view of safety safe cholecystectomy indocyanine green operative cholangiogram fluorescent imaging near-infrared imaging
action of intra-auricular topical lidocaine on tinnitus

Conditions: Tinnitus, Subjective

Summary: the main objective of this clinical trial placebo controled is to evaluate the action of intraauricular topical lidocaine on tinnitus. the question to be answered is whether lidocaine is superior to placebo (distilled water) in reducing tinnitus intensity when applied topically within the external auditory canal. tinnitus intensity will be measured using the visual analog scale and acuphenometry before and after lidocaine or placebo application.

adult patients who have had continuous, uni or bilateral tinnitus, for at least 6 months are being evaluated. exclusion criteria are: otological infection, tympanic membrane perforation, anatomical alteration of the external ear, pulsatile tinnitus, objective tinnitus, known allergy to lidocaine or other topical anesthetic and pregnancy all patients receive both lidocaine and placebo at an interval of 15 days and the order of application of the substances is randomized. only one ear receives the medications and side is defined by the higher intensity of tinnitus, or through draw in the case of symmetrical tinnitus. the patient is instructed to lie in lateral decubitus, with the ear under study facing upwards and the substances are applied by filling the external auditory canal with lidocaine or distilled water for 5 min. tinnitus intensity is measured (acuphenometry and vas) before and after substance application and the variation is compared between lidocaine and placebo.

Eligibility criteria:
inclusion criteria: * adult patients who have had continuous, uni or bilateral tinnitus, for at least 6 months exclusion criteria: * otological infection * tympanic membrane perforation * anatomical alteration of the external ear * pulsatile tinnitus * objective tinnitus * known allergy to lidocaine or other topical anesthetic and pregnancy

Keywords: tinnitus lidocaine tinnitus treatment tinnitus diagnosis tinnitus suppression
phase 3 study to evaluate iop lowering therapy in open angle glaucoma and ocular hypertension c-01-70

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: to compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.


Eligibility criteria:
adult subjects of either sex and any race with open-angle glaucoma or ocular hypertension; visual acuity of 20/80 to 20/400 or better (snellen equivalent) or logmar visual acuity not worse than 0.6. clinically relevant ophthalmic or systemic conditions may be excluded.

Keywords: open-angle glaucoma ocular hypertension poag
improving lung cancer screening adherence by overcoming barriers for vulnerable populations

Conditions: Lung Carcinoma

Summary: this study investigates multi-level barriers to lung cancer screening uptake and adherence to lung cancer screening. identifying cost- and convenience-related barriers to lung cancer screening may help researchers develop targeted strategies to facilitate screening adherence specifically among vulnerable populations.


Eligibility criteria:
inclusion criteria: * all patients referred to the jefferson lcsp and eligible for lung cancer screening by our standard criteria (united states preventive services task force, center for medicaid and medicare services, and/or national comprehensive cancer network group ii guidelines) will be eligible for inclusion in the study * additionally, individuals must provide a signed and dated informed consent form to participate in the survey portion of this study exclusion criteria: * non-english-speaking individuals * individuals who lack consent capacity
comparison of direct myofascial release and bowen's technique for non-specific neck pain

Conditions: Neck Pain

Summary: neck pain is described as pain in the neck region that may or may not radiate to both the upper limbs and that will last for at least one day. non-specific neck pain is the common cause of neck symptoms that is mainly due to mechanical causes, postural problem, depression, anxiety or occupational activities. poor posture causes abnormal muscle loading and muscle injury

neck pain is described as pain in the neck region that may or may not radiate to both the upper limbs and that will last for at least one day.poor posture causes abnormal muscle loading and muscle injury.it becomes a constant source of neck pain and instability. it reduces range of motion and weakens the shoulder and neck muscles. according to a population based survey the prevalence of lifetime neck pain ranges from 67% to 87%. trigger points cause myofascial pain syndrome which is among the leading cause of non-specific neck pain. myofascial release technique (mrt) is often used to treat non-specific neck pain.another therapy that focuses on myofascial work is bowen therapy that follows a dynamic approach to release fascia and muscles. the technique involves very gentle cross fiber movements that are applied on fascia, muscles, tendons and viscera to induce the effect. the technique is applied at specific body regions following specific sequences with regular rest intervals that cause fascial stretching. the technique consists of slightly picking up muscles and then rolling the muscles to direct them toward a specific region of body. the rest periods help the body to integrate and absorb the effects of therapy. the sensory impulses caused by the bowen therapy interact with nervous system and realign and correct the disturbed mechanisms.

Eligibility criteria:
inclusion criteria: * chronic non-specific neck pain ≥ 3 months without symptoms radiating to the upper limbs * presence of a maximum of 1-2 active myofascial trigger points * pain of more than 3 on a nprs * for the diagnosis of a trigger point, compliance with the following criteria: * (1) a hypersensitive spot in a palpable taut band, * (2) palpable or visible local twitch on pincer palpation * (3) reproduction of referred pain elicited by palpation of the sensitive spot. exclusion criteria: * diagnosed with cervical radiculopathy or myelopathy * neck pain due to trauma, fractures, or whiplash; neoplasia, severe osteoporosis, infectious, or inflammatory processes; * patients with pacemakers, congenital anomalies, previous neck surgery * patients diagnosed with fibromyalgia syndrome according to the american college of rheumatology criteria

Keywords: pain range of motion myofascial release bowen therapy anxiety